Table 2. Concentrations of CEA, CA 125, CA 15-3 and CA 19-9 in pleural effusion and/or serum according to the study cohort*.
| Variable | Beijing cohort | Wuhan cohort | Total population | |||||
|---|---|---|---|---|---|---|---|---|
| MPE (n=67) | BPE (n=107) | MPE (n=52) | BPE (n=101) | MPE (n=119) | BPE (n=208) | |||
| CEA | ||||||||
| PE, ng/mL | 69.5 | 0.6 | 82.3 | 0.8 | 76.8 | 0.7 | ||
| (7.7‒919.1) | (0.5‒1.4) | (11.0‒832.8) | (0.5‒1.4) | (8.1‒861.4) | (0.5‒1.4) | |||
| Serum, ng/mL | 4.4 | 1.5 | 7.7 | 1.7 | 5.5 | 1.7 | ||
| (2.1‒29.5) | (1.0‒2.6) | (2.0‒43.9) | (1.0‒2.5) | (2.1‒35.3) | (1.0‒2.6) | |||
| PE/serum ratio | 10.2 | 0.6 | 7.2 | 0.6 | 9.0 | 0.6 | ||
| (1.1‒29.7) | (0.4‒0.8) | (1.5‒28.3) | (0.4‒0.7) | (1.4‒28.8) | (0.4‒0.8) | |||
| ∆(PE–serum), ng/mL | 46.6 | −0.6 | 53.7 | −0.7 | 47.1 | −0.6 | ||
| (0.3‒701.6) | (−1.2‒0.2) | (4.2‒804.2) | (−1.45‒0.29) | (1.6‒728.7) | (−1.3‒0.3) | |||
| CA 125 | ||||||||
| PE, U/mL | 946.7 | 352.3 | 657.8 | 596.4 | 781.5 | 452.3 | ||
| (374.0‒2835.7) | (173.6‒780.9) | (395.1‒1366.3) | (267.1‒986.1) | (394.7‒2126.0) | (193.5‒917.2) | |||
| Serum, U/mL | 90.7 | 98.7 | 85.2 | 131.2 | 90.4 | 119.0 | ||
| (40.6‒229.2) | (55.9‒176.3) | (44.1‒222.5) | (79.1‒219.7) | (42.4‒224.6) | (65.5‒186.2) | |||
| PE/serum ratio | 8.5 | 3.4 | 6.2 | 3.9 | 7.6 | 3.8 | ||
| (4.4‒19.0) | (4.1‒7.0) | (3.3‒12.7) | (1.9‒6.8) | (3.5‒14.7) | (1.8‒6.8) | |||
| ∆(PE–serum), U/mL | 895.0 | 215.7 | 425.4 | 401.9 | 663.4 | 293.2 | ||
| (280.2‒2046.8) | (62.6‒604.0) | (205.3‒1058.6) | (122.8‒715.2) | (254.0‒1831.1) | (86.2‒761.9) | |||
| CA 15-3 | ||||||||
| PE, U/mL | 30.1 | 5.3 | 47.6 | 7.0 | 39.9 | 6.2 | ||
| (5.4‒91.7) | (3.0‒10.1) | (11.8‒176.0) | (3.4‒9.3) | (8.7‒109.0) | (3.2‒9.7) | |||
| Serum, U/mL | 15.7 | 9.1 | 21.3 | 10.9 | 18.6 | 10.2 | ||
| (8.8‒33.6) | (6.8‒13.1) | (13.3‒70.8) | (6.9‒16.0) | (10.5‒47.2) | (6.8‒14.9) | |||
| PE/serum ratio | 1.3 | 0.6 | 1.1 | 0.7 | 1.2 | 0.6 | ||
| (0.6‒3.5) | (0.3‒0.9) | (0.5‒3.5) | (0.4‒0.9) | (0.6‒3.5) | (0.4‒0.9) | |||
| ∆(PE–serum), U/mL | 8.4 | −3.4 | 4.2 | −2.7 | 7.4 | −3.3 | ||
| (−4.1‒53.7) | (−6.80‒1.0) | (−6.6‒85.2) | (−7.9 to −1.2) | (−4.7‒74.0) | (−7.0‒1.2) | |||
| CA 19-9 | ||||||||
| PE, U/mL | 24.8 | 2.0 | 13.0 | 2.4 | 23.6 | 2.0 | ||
| (2.0‒1089.2) | (1.6‒3.1) | (2.0‒291.2) | (2.0‒6.1) | (2.0‒442.4) | (2.0‒4.0) | |||
| Serum, U/mL | 14.4 | 5.0 | 8.8 | 7.4 | 12.3 | 6.2 | ||
| (5.3‒61.3) | (2.6‒9.7) | (2.5‒58.8) | (3.9‒13.2) | (4.0‒61.3) | (2.9‒12.0) | |||
| PE/serum ratio | 1.0 | 0.5 | 1.0 | 0.4 | 1.0 | 0.5 | ||
| (0.6‒9.3) | (0.3‒1.0) | (0.8‒8.8) | (0.3‒0.7) | (0.6‒8.9) | (0.3‒0.8) | |||
| ∆(PE–serum), U/mL | 0 | −2.1 | 0.6 | −4.2 | 0 | −3.2 | ||
| (−3.8‒425.4) | (−6.1‒0) | (−0.9‒237.3) | (−8.0‒1.2) | (−2.4‒285.61) | (−7.1‒0.6) | |||
*, data are presented as medians (25th to 75th percentiles). CEA, carcinoembryonic antigen; MPE, malignant pleural effusion; BPE, benign pleural effusion; PE, pleural effusion.